5,391 reports of this reaction
1.1% of all Cosentyx reports
#19 most reported adverse reaction
PERIPHERAL SWELLING is the #19 most commonly reported adverse reaction for Cosentyx, manufactured by Novartis Pharmaceuticals Corporation. There are 5,391 FDA adverse event reports linking Cosentyx to PERIPHERAL SWELLING. This represents approximately 1.1% of all 494,338 adverse event reports for this drug.
Patients taking Cosentyx who experience peripheral swelling should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PERIPHERAL SWELLING is a less commonly reported adverse event for Cosentyx, but still significant enough to appear in the safety profile.
In addition to peripheral swelling, the following adverse reactions have been reported for Cosentyx:
The following drugs have also been linked to peripheral swelling in FDA adverse event reports:
PERIPHERAL SWELLING has been reported as an adverse event in 5,391 FDA reports for Cosentyx. This does not prove causation, but indicates an association observed in post-market surveillance data.
PERIPHERAL SWELLING accounts for approximately 1.1% of all adverse event reports for Cosentyx, making it a notable side effect.
If you experience peripheral swelling while taking Cosentyx, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.